Cigna Medicare Advantage GLP-1 Coverage: What HealthSpring Covers and the $50 Bridge

Cigna Medicare Advantage GLP-1 coverage now runs through HealthSpring. Its 2026 rules list Ozempic and Mounjaro with prior authorization for FDA-approved uses such as type 2 diabetes; your exact plan controls coverage. Basic Part D excludes weight loss alone. The separate Medicare GLP-1 Bridge can pay: $50 per 28- or 30-day supply if you qualify.

Three things decide your answer: why the drug is prescribed, what kind of plan your card shows, and whether a Medicare drug plan already paid for a GLP-1 in 2026. The table below shows where to start. That last one is the catch to check before you count on $50.

RX Index Decision Verdict: Check your HealthSpring benefit and the reason on your prescription before you pay anyone for anything.

• Best for: current or former Cigna Medicare Advantage members, and family helping them, who want a GLP-1 covered.
• Not ideal for: Cigna through a job or the Marketplace. Our Cigna coverage guide fits you better.
• The factor that matters most: why the drug is prescribed. That fact tells you which rules to check first.

We can't see your plan, and no website can promise you an approval. What we can do is show you which door to knock on, what to bring, and what to say when you get there.

id="cigna-medicare-advantage-glp-1-coverage-which-door">Cigna Medicare Advantage GLP-1 coverage: which door?

For a HealthSpring member with drug coverage, there are two systems to check. A GLP-1 prescribed for an eligible medical use—such as type 2 diabetes, heart-risk reduction, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH with F2–F3 scarring—belongs with HealthSpring Part D. Weight management alone may go through the federal $50 Medicare GLP-1 Bridge, which HealthSpring doesn't run.

Before you read the table, find three things: the plan name on your card, the exact drug and form on the prescription, and the reason your clinician wrote it. If you have those, you're ready.

A few quick definitions. Part D is Medicare drug coverage. If your Medicare Advantage plan covers prescriptions, Part D is built into it. Prior authorization is a permission slip: the plan or program has to OK the drug before it pays for it. A copay is a fixed amount you pay; coinsurance is a percentage of the cost.

We built this table from HealthSpring's 2026 Medicare Advantage prior-authorization criteria (updated Sept. 1, 2026), HealthSpring's 2026 Standard 5-Tier formulary guide, CMS's Bridge rules for drug plans (updated Aug. 6, 2026) and pharmacies (updated Aug. 17, 2026), and the current Wegovy label and Zepbound label. "Your door" is our reading of those rules. It tells you where to ask. It isn't an approval.

MASH means metabolic dysfunction-associated steatohepatitis: a liver disease involving fat buildup and inflammation. The coverage use above is for adults with F2–F3 fibrosis, meaning moderate-to-advanced scarring without cirrhosis. CMS is the Centers for Medicare & Medicaid Services, the federal agency running the Bridge.

What we actually verified Checked September 24, 2026: HealthSpring's 2026 Medicare Advantage prior-authorization criteria, Standard 5-Tier guide, and two public formularies; its drug list, plan document, coverage decision, appeal, and annual-change pages; its notices about the switch from Cigna; Cigna's SEC filing and HCSC's sale announcement; CMS's Bridge pages for plans, prescribers, and pharmacies, prescriber fact sheet, and pharmacy reject-code guide; Medicare.gov's drug-cost, weight-loss drug, enrollment, contact, and drug-appeal pages; current Wegovy, Zepbound, Mounjaro, Ozempic, Rybelsus, and Trulicity prescribing information; the FDA's Foundayo approval announcement and compounding guidance; and manufacturer savings terms. How to read it: HealthSpring's rules are the plan's own published policy. Drug uses come from FDA labels. The door table is our synthesis. What we couldn't confirm: your plan's copay and tier, whether your exact plan covers Wegovy or Zepbound for an eligible heart, sleep, or liver use, your 2027 benefits, or your pharmacy's stock. We found 2026 documents on the public HealthSpring pages we checked; that does not establish whether your own 2027 documents are available. What we didn't do: submit a claim, call HealthSpring as a member, or get a coverage decision for anyone. No clinician reviewed this page. It explains coverage rules, not medical care. The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation. Here's how we check our work.

Your Medicare coverage comes first. But if the table leaves you with more than one road, the right GLP-1 path isn't the same for everyone. It depends on your state, your plan and its drug list, FDA-approved or compounded medication, a shot or a pill, and your budget. Compounded drugs are not FDA-approved and are not Bridge products. The RX Index's Find My GLP-1 Path tool asks a few quick questions, then shows the GLP-1 paths and providers that fit your goals, budget, insurance, and situation. It's free, takes about 2 minutes, and needs no signup. It doesn't decide Medicare coverage. It helps you compare what's left.

See which GLP-1 path fits you

What happened to Cigna Medicare Advantage?

Cigna sold its Medicare Advantage, Medicare Part D, and Medicare supplement businesses to Health Care Service Corporation (HCSC), and the sale closed March 19, 2025. Starting January 2026, former Cigna Medicare Advantage members moved into HealthSpring plans with new HealthSpring ID cards. Cigna's pharmacy company, Evernorth, still provides pharmacy benefit services to these plans for an agreed period.

That's from Cigna's own filing with the SEC, HCSC's announcement, and HealthSpring's notices from November 2025 and January 2026.

Why does a name change matter for your drugs? Because the wrong rulebook leads to the wrong answer.

If you search "Cigna GLP-1 coverage," you'll find long Cigna policy PDFs with BMI rules and lifestyle requirements. Those policies say they apply to plans run by Cigna companies, like employer plans. Your Medicare plan isn't run by Cigna anymore. Your rules are HealthSpring's Medicare rules plus federal Medicare rules.

You'll still see one familiar name: Express Scripts. HealthSpring's drug coverage requests and drug appeals are mailed to Express Scripts, and HealthSpring uses Express Scripts Pharmacy for home delivery. That's normal. It doesn't mean Cigna's employer rules apply to you.

If your drug card names a former employer, ask that plan's administrator which rules apply. Group plans can have their own drug lists.

What HealthSpring's 2026 drug rules say about GLP-1s

HealthSpring's 2026 Medicare Advantage prior-authorization rules list Ozempic, Mounjaro, Rybelsus, and Trulicity in one GLP-1 entry. That entry asks for your diagnosis, lists all FDA-approved indications, gives a one-year authorization period, and doesn't require trying another drug first. The entry doesn't include Wegovy, Zepbound, or Foundayo.

Here's what HealthSpring's own documents show, in plain English:

Compounded products, separately: Compounded semaglutide and tirzepatide are not FDA-approved, are not listed in the HealthSpring drug lists we checked, and are not Bridge products. FDA explains the approval distinction.

Sources: HealthSpring's 2026 MAPD prior-authorization criteria (printed page 115, "GLP-1 AGONISTS"; updated Sept. 1, 2026), HealthSpring's 2026 Standard 5-Tier guide, and the FDA's Foundayo approval announcement (April 1, 2026). Checked Sept. 24, 2026.

Two cautions. First, your plan may use a different HealthSpring drug list than the Standard 5-Tier one, so your tier could differ. Second, "not in this entry" doesn't mean "not covered." It means you need to check your own plan's list. We also searched the public Primary formulary and Total Care/Total Care Plus formulary we reviewed: neither contained Wegovy or Zepbound. Those two lists do not establish coverage for every HealthSpring plan.

Our read of the diagnosis requirement: it's how the plan confirms the drug is for an approved use, like type 2 diabetes, and not weight loss alone.

Say you're 72, on a HealthSpring HMO, with type 2 diabetes. A friend lost weight on Zepbound, and you want it too. Diabetes closes the $50 Bridge door for you. But Mounjaro, which contains tirzepatide like Zepbound and is approved for type 2 diabetes, is on the Standard 5-Tier list with prior authorization. Ask your clinician whether it fits you. Which drug is right, and whether any GLP-1 is safe for you, is your clinician's call. Mounjaro prescribing information; Zepbound prescribing information.

How to check your exact plan

1. Find your contract number on your HealthSpring ID card.
2. Open HealthSpring's Plan Document Search. No contract number? Pick the "I don't know" option and search for your plan. You don't have to buy anything to see your documents.
3. Open your plan's drug list (also called a formulary) and your Evidence of Coverage, the booklet that explains what you pay for each tier.
4. Use the Medicare Advantage drug list, not the one for HealthSpring's standalone drug plans. They're different lists.
5. Search the exact brand and form, like "Wegovy tablet" or "Zepbound KwikPen," not just "semaglutide."

Use your exact plan before you count on a tier or a price.

Check my HealthSpring drug list

Can you get the $50 Medicare GLP-1 Bridge with a HealthSpring plan?

Yes, if you qualify. The Medicare GLP-1 Bridge is a federal program that runs July 1, 2026 through December 31, 2027, and drug plans don't have to sign up for their members to use it. HealthSpring Medicare Advantage plans with drug coverage are an eligible plan type, but the prescription must be for weight management and you must meet Medicare's health rules.

This comes straight from CMS's rules for drug plans. The Bridge sits outside your plan's normal drug coverage. So HealthSpring doesn't approve it, pay for it, or get a vote.

Step 1: Confirm your plan type

Source: CMS pharmacy guidance, updated Aug. 17, 2026. Please don't add or drop a plan to chase the Bridge without advice. Some changes can end your Medicare Advantage enrollment. Call 1-800-MEDICARE first.

Step 2: Check the drug and its exact form

The Bridge covers three brands, and the form matters:

• Foundayo (orforglipron) tablets
• Wegovy, both the shot and the tablets
• Zepbound KwikPen only. Not Zepbound vials. Not Zepbound single-dose pens.

Ozempic, Mounjaro, and Rybelsus aren't Bridge drugs. Neither is any compounded product.

Step 3: Check your starting BMI

BMI (body mass index) is a number based on your height and weight. Medicare uses your BMI when you started GLP-1 treatment, not today's. You must also be 18 or older, and the prescription has to be for weight management with ongoing structured nutrition and physical activity consistent with the drug label.

Meet any one row:

Source: CMS clinical criteria on its drug plan page. Checked Sept. 24, 2026.

The rows overlap. A starting BMI of 32 plus prediabetes meets the "27 or higher" row. You don't also need something from the "30 or higher" row. That's how the rows work, not a promise you'll be approved.

Lost weight already? Good news: CMS looks at your BMI when you started. Ask your clinician's office for the weight or BMI recorded when you began any GLP-1. If you've never taken one, your BMI when you start is the one that counts.

Step 4: Check what closes the Bridge door

Hitting a BMI row isn't the whole test. Four things can send you somewhere else:

1. Type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH with moderate-to-advanced scarring (F2–F3 fibrosis). CMS says these go through your HealthSpring drug plan, even if HealthSpring doesn't cover a GLP-1 for that condition.
2. A prescription written to lower heart attack or stroke risk. Heart disease by itself doesn't close the door. But if the drug is prescribed to reduce major heart events, CMS routes it to your plan, even if weight loss is also a goal. Your clinician states the real reason.
3. A 2026 GLP-1 fill paid by a Medicare drug plan. If any Medicare drug plan paid for Zepbound, Mounjaro, Foundayo, Rybelsus, Ozempic, Wegovy, Saxenda, Victoza, or Trulicity in 2026, you can't use the Bridge in 2026. That includes a fill paid through a group plan's extra weight-loss benefit. CMS hasn't set the 2027 rule yet as of our Sept. 24, 2026 check.
4. Later changes. If you're approved and a Medicare drug plan later pays for a GLP-1, or you move to an ineligible plan type, your Bridge access ends.

Say you're 66 and had a heart attack two years ago. In May, HealthSpring paid for Wegovy to lower your heart risk. Now you've heard about the $50 program. That May fill closes the Bridge for the rest of 2026, and a heart-risk prescription belongs with your plan anyway. You didn't do anything wrong. You're just already in the other lane.

Paying cash for a GLP-1 isn't the same as a drug plan paying for it. CMS's rule is about fills covered by a Medicare drug plan.

Medicare's own page walks through a few questions to see if the Bridge might fit you. It's a starting point, not an approval.

Check Medicare's $50 program rules

Want every rule and the exact form questions in one place? Our Bridge eligibility checklist goes deeper.

Wegovy for heart risk, Zepbound for sleep apnea, Wegovy for MASH: why these stay with HealthSpring

CMS treats major heart-event risk reduction, moderate-to-severe obstructive sleep apnea, and noncirrhotic MASH with F2–F3 scarring as uses Medicare drug plans can cover with the appropriate drug. A prescription for one of these goes to HealthSpring, not the Bridge, even if the drug isn't on HealthSpring's list. HealthSpring must use its normal exception process, and CMS says it's watching for plans that push these requests onto the Bridge.

That's in CMS's guidance for drug plans. This trips people up, because the natural thought is "My plan said no, so I'll use the $50 program." For these three uses, that doesn't work. The fix is inside HealthSpring.

Here's the path:

1. Check your 2026 drug list for the exact drug and form.
2. If it's listed and requires prior authorization, your prescriber sends that request with your records.
3. If it's not listed, ask for a formulary exception. That's a request to cover a drug that isn't on the list. Your prescriber writes a statement about why you need it.
4. If HealthSpring says no in writing, you can appeal. The steps are further down.

What to have ready: relevant records such as a sleep study for sleep apnea, liver-stage results for MASH, or records of established cardiovascular disease for heart risk. Your exact plan decides which records it requires. The Wegovy MASH indication is under accelerated approval; continued approval may depend on confirmation of clinical benefit in a trial. Wegovy label.

One honest rule: never ask a clinician to change the reason on a prescription to get a cheaper door. Your prescriber signs the Bridge form, and CMS can check it. The real reason is the only safe reason.

What will you pay, and what isn't included?

The Bridge's $50 is a drug copay for one approved 28- or 30-day supply, not a bill for all your care. What you pay through HealthSpring depends on your plan, tier, and pharmacy. The two systems also count differently toward Medicare's yearly drug cap.

Sources: Medicare.gov drug costs, CMS pharmacy guidance, HealthSpring coverage decisions. Checked Sept. 24, 2026.

The math on $50. Some supplies are 28 days, like a 28-day billing cycle that doesn't line up with calendar months. So:

• 4 fills of 28 days = $200 for 112 days
• 12 fills of 28 days = $600 for 336 days, which is short of a full year
• 13 fills of 28 days = $650 for 364 days

That's arithmetic, not a dosing schedule. Visits, tests, and needles are outside this drug-only total. Check their actual cost; an unknown cost isn't zero.

The cap catch. Once qualifying out-of-pocket spending on covered Part D drugs hits the yearly cap, those drugs cost $0 for the rest of the year, per Medicare.gov. Bridge copays don't count toward that cap. Say your qualifying spending on several other brand-name drugs reaches the 2026 limit of $2,100. After that, a GLP-1 your plan covers could cost $0, while a Bridge fill still costs $50. That's not a reason to change why a drug is prescribed. Your clinician decides that honestly. It's just how the money works. More detail: Bridge out-of-pocket costs.

How to get it done: who does what

Your plan, your prescriber, and your pharmacy each have a different job. For a HealthSpring drug request, your prescriber usually starts it. For the Bridge, the pharmacy claim comes first and the paperwork second.

HealthSpring Part D: ask for a coverage decision

A coverage decision is HealthSpring's formal answer about a drug. A pharmacy rejection isn't always the final word. It may just mean more information is needed.

You, your prescriber, or someone you name can ask. Your prescriber's written statement explains the medical reason.

• Phone: 1-877-813-5595 (TTY 711), 8 a.m. to 2 a.m. Monday to Friday, 8 a.m. to 8 p.m. Saturday
• Fax: 1-866-845-7267
• Online: HealthSpring's coverage decision page links to an online request form through Express Scripts.

Timing for a coverage request: a standard decision comes within 72 hours after HealthSpring receives the request. A fast decision comes within 24 hours when your health requires it. For an exception, the clock starts when HealthSpring gets your prescriber's statement. Source: HealthSpring, checked Sept. 24, 2026.

The $50 Bridge: pharmacy claim first, paperwork second

Order matters here. Get it backward and the system says "patient not found," which looks like a denial but isn't one. That comes from CMS's prescriber guidance.

1. Your clinician decides the Bridge fits and sends the prescription to your pharmacy. CMS recommends they note the Bridge and a diagnosis code on the prescription. It isn't required, but it helps the pharmacy route it.
2. The pharmacy sends the claim to the Bridge, not to HealthSpring, using your Medicare number.
3. If the enrollment and product checks pass, the system answers "prior authorization required." That's normal. It's a step, not a no.
4. The pharmacy sends the request to your prescriber, usually within 24 to 72 hours, per CMS's prescriber fact sheet.
5. Your prescriber submits the Bridge form. The decision is mailed to you and sent to your prescriber through the electronic portal or by fax within 72 hours of submission.

If the pharmacy has sent the Bridge claim but your prescriber still has no authorization request after 72 hours, CMS says the prescriber can download the fax form from its provider instructions and submit it. That avoids waiting on a request that has not arrived.

After approval, your authorization is good through December 31, 2027. Refills and dose changes don't need a new approval unless you switch to a different GLP-1. Source: CMS pharmacy guidance.

After your clinician has checked that the Bridge fits, say this at the pharmacy counter: "Can you send this to the Medicare GLP-1 Bridge instead of my HealthSpring plan? Here's my Medicare card. The BIN is 028918 and the PCN is MEDDGLP1BR."

A decision in 72 hours isn't a promise your pharmacy has the drug on the shelf. Ask about stock when you drop off the prescription.

Your call worksheet

A missing fact can stall a call. This worksheet keeps the facts and next steps together. Print it, fill it in by hand, and bring it to every call. Don't send any of this to us. Share it only with your plan, clinician, or pharmacy.